Prosecution Insights
Last updated: August 18, 2026

Inovio Pharmaceuticals Inc.

15 pending office actions • 6 art units • 14 examiners • 0 of 15 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days

Portfolio Summary

15
Total Pending OAs
8
Non-Final OAs
7
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
1
Due this month
2
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (1)Due ≤ 60 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

7
Hard (47%)
4
Medium (27%)
3
Easy (20%)
1
Unknown (7%)

Rejection Statute Mix

BucketCases
§101 + other2 (13%)
§103 only2 (13%)
§102 only1 (7%)
§112 only1 (7%)
Double-patenting only2 (13%)
Double-patenting + other1 (7%)
Multi-statute (no §101)5 (33%)
No statute on record1 (7%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

10
Life Sciences
67% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
1
Semiconductors
7% of docket
4
Mechanical / Eng
27% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

150 h
Manual time on pending OAs
30 h
Time saved (low, 20%)
52 h
Time saved (mid, 35%)
1.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ZOU, NIANXIANG 2 64.0% +24.4%
STUART, CAREY ALEXANDER MC 1 58.3% +41.6%
HILL, MYRON G 1 66.2% +20.3%
FARRAR, LAUREN PENG 1 78.7% +15.3%
GILL, RACHEL B 1 65.4% +28.0%
ALAM, DANYAL HASSAN 1 66.7% +0.0%
PARKIN, JEFFREY S 1 63.7% +21.3%
HENZE, DAVID V 1 70.2% +23.4%
FOLEY, SHANON A 1 73.2% +18.0%
ALAWADI, SARAH 1 37.7% +38.4%

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
17855349 Side-Port Injection Devices For Use With Electroporation, and Related Systems and Methods RODRIGUEZ, CRIS LOIREN 5d overdue
18493133 LASSA VIRUS VACCINE AND USES THEREOF GILL, RACHEL B 34d
18493936 Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) HILL, MYRON G
18493512 Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods FARRAR, LAUREN PENG
18300588 Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) ALAM, DANYAL HASSAN
18174298 Handheld Electroporation Devices, And Related Systems And Methods HENZE, DAVID V
17688429 ELECTROPORATION DEVICE HAVING A BATTERY PACK WITH POWER SWITCH GEDEON, BRIAN T

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18503487 Vaccines For Human Papilloma Virus And Methods For Using The Same ZOU, NIANXIANG 138d overdue
18493133 LASSA VIRUS VACCINE AND USES THEREOF GILL, RACHEL B 34d
18045575 TERT IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME ALAWADI, SARAH 34d
18593320 METHODS OF TREATMENT OF HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) STUART, CAREY ALEXANDER MC
18493936 Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) HILL, MYRON G
18493512 Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods FARRAR, LAUREN PENG
18300973 Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use PARKIN, JEFFREY S
18174298 Handheld Electroporation Devices, And Related Systems And Methods HENZE, DAVID V

Top Art Units

Art UnitApps
1671 7
3783 3
1672 2
2859 1
1619 1
3796 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18593320 METHODS OF TREATMENT OF HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) STUART, CAREY ALEXANDER MC 1671 §102§103§112DP Non-Final OA Pending Mar 01, 2024
18503487 Vaccines For Human Papilloma Virus And Methods For Using The Same ZOU, NIANXIANG 1671 DP Non-Final OA 138d overdue Pending Nov 07, 2023
18493936 Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) HILL, MYRON G 1671 §101§103 Non-Final OA Pending Oct 25, 2023
18493512 Vacuum-Assisted Agent Delivery Devices, and Related Systems and Methods FARRAR, LAUREN PENG 3783 §102§103 Non-Final OA Pending Oct 24, 2023
18493133 LASSA VIRUS VACCINE AND USES THEREOF GILL, RACHEL B 1671 §102§103§112Other Non-Final OA 34d Pending Oct 24, 2023
18300588 Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) ALAM, DANYAL HASSAN 1672 §101§103 Final Rejection Pending Apr 14, 2023
18300973 Immunogenic Compositions Against SARS-COV-2 Variants And Their Methods Of Use PARKIN, JEFFREY S 1671 §112 Non-Final OA Pending Apr 14, 2023
18174298 Handheld Electroporation Devices, And Related Systems And Methods HENZE, DAVID V 2859 §102§103 Non-Final OA Pending Feb 24, 2023
18048776 COMPOSITIONS AND METHODS FOR TREATING ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) FOLEY, SHANON A 1671 DP Final Rejection Pending Oct 21, 2022
18045575 TERT IMMUNOGENIC COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME ALAWADI, SARAH 1619 §102Other Final Rejection 34d Pending Oct 11, 2022
17813762 CANCER VACCINES AND METHODS OF TREATMENT USING THE SAME SALVOZA, M FRANCO G 1672 Other Non-Final OA 28d Pending Jul 20, 2022
17855349 Side-Port Injection Devices For Use With Electroporation, and Related Systems and Methods RODRIGUEZ, CRIS LOIREN 3783 §103§112 Final Rejection 5d overdue Pending Jun 30, 2022
17688429 ELECTROPORATION DEVICE HAVING A BATTERY PACK WITH POWER SWITCH GEDEON, BRIAN T 3796 §102§103 Final Rejection Pending Mar 07, 2022
17221032 COMPOSITIONS AND METHODS FOR TREATING VULVAR DYSPLASIA ZOU, NIANXIANG 1671 §103 Final Rejection Pending Apr 02, 2021
16804707 VARIABLE CURRENT DENSITY SINGLE NEEDLE ELECTROPORATION SYSTEM AND METHOD VU, QUYNH-NHU HOANG 3783 §103 Final Rejection 37d overdue Pending Feb 28, 2020

Managing Inovio Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month